Deep Genomics

Toronto, Canada All Canada companies → — Founded 2014

AI Research Lab Biotech / Drug Discovery Specialty-Focused AI

Neurology Oncology Pediatrics

Drug Discovery & Research

Series C

Website Claim this company

Products

AI Workbench

Deep Genomics

Drug Discovery & Research

Deep Genomics is an AI-driven drug discovery company that decodes RNA biology to find novel targets, mechanisms, and molecules for RNA-based drug candidates, focusing on genetic diseases.

See all 1 product →

About Deep Genomics

Deep Genomics is a leading artificial intelligence (AI) therapeutics company that is revolutionizing drug discovery and development for genetic diseases. The company leverages a proprietary AI-powered discovery platform, known as the AI Workbench, which integrates machine learning algorithms with vast genomic data. This platform allows Deep Genomics to analyze billions of predictions across the human genome, for millions of genetic variants, and hundreds of millions of novel compounds, a level of productivity unattainable through traditional methods.

Deep Genomics’ core focus is on decoding RNA biology to identify novel therapeutic targets and develop innovative RNA-based treatments. Their technology helps accelerate the early stages of drug discovery and the design of RNA-based therapies, including oligonucleotides, RNA editing, and mRNA. They aim to develop precision therapies tailored to individual genetic profiles, with an initial focus on central nervous system (CNS) and metabolic diseases.

Focus Areas

genetic medicine RNA therapies artificial intelligence machine learning drug discovery genomics rare diseases metabolic disorders neurological conditions

Business Intelligence

Technology

BioFM Platform (Biological Foundation Models), AI Workbench, BigRNA (proprietary BioFM)

What Physicians Need to Know

Genetic Medicine & RNA Therapies

Deep Genomics specializes in programming and prioritizing transformational RNA therapies for genetic conditions. They focus on developing steric blocking oligonucleotides (SBOs), which can both increase and decrease gene expression, offering more control than other RNA therapies.

Artificial Intelligence & Machine Learning

The company leverages AI and machine learning to decode RNA biology, identify novel targets for genetically defined diseases, and design therapeutic programs with a high success rate. Their AI Workbench platform is central to this process, enabling them to analyze vast amounts of data and predict the consequences of genetic mutations.

Drug Discovery

Deep Genomics aims to revolutionize drug discovery by using AI to move beyond traditional trial-and-error methods, reducing time and costs while improving precision and efficacy. They have successfully identified drug candidates for rare diseases like Wilson disease in significantly less time than traditional methods.

Genomics

Their work is rooted in human genomics, utilizing deep learning to interpret genetic mutations and identify therapeutic targets. They aim to translate genetic knowledge into life-saving medicines.

Rare Diseases

Deep Genomics is dedicated to developing drugs and therapies for rare and complex ailments that currently lack cures. They have active programs and partnerships focused on rare diseases, including Wilson disease, Niemann-Pick disease type C, and Frontotemporal Dementia.

Metabolic Disorders

The company is actively researching and developing preclinical therapies for metabolic disorders, with a focus on conditions like Wilson disease.

Neurological Conditions

Deep Genomics is advancing programs in neurodevelopmental and neurodegenerative disorders, including Frontotemporal Dementia and Niemann-Pick disease type C.

Physician Tip

Deep Genomics' AI-driven platform, particularly their BioFM Platform and BigRNA model, offers physicians the potential for genetically precise therapies for diseases currently without cures. Their approach can lead to faster identification of drug candidates and a higher preclinical success rate compared to traditional methods. This means a future with more targeted and effective treatment options for patients with genetic, metabolic, and neurological conditions, including rare diseases. The ability of their SBOs to both increase and decrease gene expression provides a versatile therapeutic approach. Physicians can anticipate a growing pipeline of AI-discovered RNA therapies addressing the root genetic causes of diseases.

Deep Genomics' platform, including the AI Workbench and BioFM Platform, is designed to integrate AI, software engineering, and RNA biology. They also offer GenomeKit, a tool to streamline genomic sequence analysis for researchers. Their strategy includes strategic partnerships with pharmaceutical companies to accelerate the R&D process and translate AI insights into viable therapeutics. Their technology stack includes Kubeflow, NetSuite, Keras, Microsoft Windows, Bash, Microsoft Azure, C++, and Python.

Products by Deep Genomics

1 product in the directory

AI Workbench

Deep Genomics

Drug Discovery & Research

Deep Genomics is an AI-driven drug discovery company that decodes RNA biology to find novel targets, mechanisms, and molecules for RNA-based drug candidates, focusing on genetic diseases.

What the Web Says

Deep Genomics is a biotechnology company that leverages AI, machine learning, and RNA biology to discover and develop genetic medicines for rare and complex diseases. The company aims to develop therapies for conditions that currently lack cures, focusing on central nervous system and metabolic diseases. While employee sentiment has been mixed, the company is recognized for its innovative approach to drug discovery.

Overall: Mixed

Strengths

Pioneering use of AI and machine learning in drug discovery for genetic diseases.
Focus on developing therapies for rare and complex ailments with unmet medical needs.
Strong scientific team with expertise in various relevant fields.
Highly rated by employees for manager, environment, perks, benefits, and CEO.
Integrated AI Workbench used across all business activities, from target identification to molecule design.
Significant funding rounds, indicating strong investor confidence.

Limitations

Overall employee sentiment has been negative and declining year-over-year in 2026.
The company does not offer commercial genetic testing or counseling.
Limited publicly available product reviews from independent healthcare IT reviewers, G2, Capterra, or Glassdoor.
Reddit discussions are primarily about job interviews or general AI in biotech, not specific company or product reviews.
Workforce declined by 19.6% from 2023 to 2026, although it is up 5.5% year-over-year in 2026.
KPIs and OKRs are not consistently clear across all departments.

Based on reviews from: Comparably, Deep Genomics review - 7 facts you should know [DECEMBER 2021], Revelio Labs, CIO Bulletin, Indeed.com, Reddit, Built In, Deep Genomics | AI-Driven Discovery of Genetic Medicines, Ladders, Medium

Last updated: 2026-08-24

Videos

News, demos, and interviews about Deep Genomics.

Loading videos...

Videos load interactively. If none appear, search YouTube for Deep Genomics →

View all on YouTube

Press & Coverage

Business Wire

Deep Genomics Appoints Thong Q. Le as Chair of the Board of Directors

Deep Genomics announced the appointment of Thong Q. Le as chair of its Board of Directors, effective July 23, 2026. Le, who joined the board in 2025, will guide the company in advancing its pipeline, expanding collaborations, and strengthening its leadership in AI, genomics, and drug discovery.

2026-07

STAT+

Deep Genomics founder: Why AI for drug discovery will far exceed current expectations

Brendan Frey, founder of Deep Genomics, discusses in this article from June 2025 why he believes AI for drug discovery will significantly surpass current expectations. The article highlights the potential of AI in transforming the pharmaceutical industry.

2025-06

Methods Mol Biol

Deep Genomics: Deep Learning-Based Analysis of Genome-Sequenced Data for Identification of Gene Alterations

This peer-reviewed article from 2025 surveys the evolving landscape of deep genomics, emphasizing how deep learning frameworks enable researchers to detect, characterize, and interpret complex genetic alterations. It highlights the convergence of next-generation sequencing and advanced computational methods in reshaping genomic analysis.

2025-06

Drug Discovery and Development

Deep Genomics Expands AI Platform for RNA Therapies

Deep Genomics expanded its operations in June 2024 by opening a new office and lab in Cambridge, Massachusetts, alongside leadership hires. The company aims to develop RNA therapies for genetic diseases using its AI Workbench platform, focusing on metabolic and neurological disorders.

2024-06

Fierce Biotech

Deep Genomics puts forward AI model for generating RNA therapies

Deep Genomics introduced its AI-powered foundation model, BigRNA, in September 2023, designed to explore RNA biology and its role in diseases, and to identify avenues for new therapies. The model, built from a trillion genomic signals, aims to predict biological mechanisms regulating RNA expression.

2023-09

Deep Genomics

Deep Genomics Announces the Appointment of Brian O'Callaghan as CEO

Deep Genomics announced the appointment of Brian O'Callaghan as CEO in September 2023, as part of its plan to evolve into a forward-integrated biopharmaceutical company. Founder Brendan Frey transitioned to Chief Innovation Officer.

2023-09

Deep Genomics

Deep Genomics Raises $180M in Series C Financing

Deep Genomics closed a $180 million Series C financing round in July 2021, led by SoftBank Vision Fund 2. This funding will support the advancement of its AI discovery platform for 'Programmable' RNA therapeutics and accelerate its portfolio toward clinical trials.

2021-07

PR Newswire

BioMarin and Deep Genomics to Collaborate on Advancing Programs Identified Using Artificial Intelligence

BioMarin Pharmaceutical Inc. and Deep Genomics announced a preclinical collaboration in November 2020 to use Deep Genomics' AI Workbench to identify oligonucleotide drug candidates for four rare disease indications. Deep Genomics will receive an upfront payment and is eligible for development milestones.

2020-11

Frequently Asked Questions

How does Deep Genomics' AI-driven platform accelerate the discovery and development of genetic medicines, particularly RNA therapies, for rare diseases and other conditions?

Deep Genomics utilizes an AI-driven platform to analyze vast amounts of genomic data and identify disease-causing genetic variations. This platform helps predict the impact of these variations and design novel RNA therapies that can correct or compensate for the genetic defects, thereby accelerating the drug discovery process for conditions like rare diseases, metabolic disorders, and neurological conditions.

What specific types of genetic conditions, such as metabolic disorders or neurological conditions, are Deep Genomics' current drug discovery programs focused on, and what is the status of these programs?

Deep Genomics' drug discovery programs are focused on a range of genetic conditions, including various rare diseases, metabolic disorders, and neurological conditions. While specific program details and their exact status (e.g., preclinical, clinical trial phases) would require direct inquiry with the company, their platform is designed to be broadly applicable across diseases with a genetic basis.

What is Deep Genomics' approach to ensuring the compliance and regulatory approval of their AI-discovered and developed genetic medicines, especially concerning novel RNA therapies?

Deep Genomics integrates compliance considerations throughout its drug discovery and development process. Their AI platform aims to identify drug candidates with favorable safety and efficacy profiles, which are crucial for regulatory approval. They likely work closely with regulatory bodies to ensure their novel RNA therapies meet all necessary guidelines and standards.

Can you provide information on the typical pricing structure or economic models for Deep Genomics' genetic medicines, particularly for healthcare systems or institutions treating patients with rare diseases?

Deep Genomics' specific pricing structures for their genetic medicines would be determined upon successful development and market entry. These models often vary based on the therapeutic area, patient population size (especially for rare diseases), and the overall value proposition of the treatment. Direct engagement with Deep Genomics would be necessary for detailed pricing information.

What kind of support and partnership opportunities does Deep Genomics offer to healthcare providers and research institutions interested in collaborating on genetic medicine research or patient access programs?

Deep Genomics actively seeks partnerships with healthcare providers and research institutions to advance genetic medicine. These collaborations can range from research partnerships to explore new therapeutic targets or disease mechanisms, to potential programs aimed at improving patient access to their developing therapies. They likely offer scientific and potentially logistical support for such collaborations.

How does Deep Genomics leverage machine learning and artificial intelligence to enhance the precision and reduce the timeline of drug discovery for complex genetic disorders?

Deep Genomics leverages machine learning and AI to analyze vast and complex genomic datasets, allowing for the rapid identification of disease-causing genetic mutations and the prediction of their functional consequences. This capability significantly enhances the precision of drug target identification and streamlines the design of therapeutic molecules, thereby reducing the overall timeline for developing treatments for complex genetic disorders.

What is the long-term vision and company stability of Deep Genomics, especially concerning its ability to bring multiple genetic medicine candidates through clinical development and to market?

Deep Genomics' long-term vision is centered on transforming genetic medicine through its AI-driven platform, aiming to bring multiple innovative therapies to patients. Their stability is supported by ongoing research and development, strategic partnerships, and investment in their technology. Their ability to bring candidates to market will depend on the success of their clinical trials and regulatory approvals.